💊

Trisenox

arsenic trioxide

Leucemia promielocitica acuta

✅ Autorizzato

✅

Nessun allarme attivo

Questo medicinale non presenta carenze in corso, lettere di sicurezza o richiami.

A cosa serve

Trisenox is indicated for induction of remission, and consolidation in adult patients with: Newly diagnosed low-to-intermediate risk acute promyelocytic leukaemia (APL) (white blood cell count, ? 10 x 103/µl) in combination with all?trans?retinoic acid (ATRA) Relapsed/refractory acute promyelocytic leukaemia (APL) (previous treatment should have included a retinoid and chemotherapy) characterised by the presence of the t(15;17) translocation and/or the presence of the Pro-Myelocytic Leukaemia/Retinoic-Acid-Receptor-alpha (PML/RAR-alpha) gene. The response rate of other acute myelogenous leukaemia subtypes to arsenic trioxide has not been examined.

⚠️ Sicurezza del paziente

📚 Avvisi passati (2)

Medio EU risolto 8 anni fa

Trisenox

Trisenox Principio attivo: triossido di arsenico · Forma: soluzione per infusione · Uso: leucemia promielocitica acuta · Alternative: sì

Medio EU risolto 8 anni fa

Trisenox

INN: arsenic trioxide · Forms: Solution for infusion · Area: Leukemia, Promyelocytic, Acute · Alternatives: Yes

Pagina ufficiale EMA

https://www.ema.europa.eu/en/medicines/human/EPAR/trisenox